SCHEMBL640001

SCHEMBL640001

CC1(C)c2ccccc2S(=O)(=O)N1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 5/20 0.35
CA2 P00918 3/20 0.35
CA12 O43570 4/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NOX1 Q9Y5S8 1/20 0.32
HSD11B1 P28845 1/20 0.32
GAA P10253 1/20 0.32
GPR3 P46089 1/20 0.31
CYP1A2 P05177 2/20 0.30
CYP2C9 P11712 2/20 0.30
CYP2C19 P33261 1/20 0.30
HTT P42858 1/20 0.30
CDC25A P30304 1/20 0.30
CDC25B P30305 1/20 0.30
CDC25C P30307 1/20 0.30
LMNA P02545 1/20 0.30
HIF1A Q16665 1/20 0.30
CA1 P00915 2/20 0.30
ELANE P08246 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8924383 0.80 CDK2 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL12059117 0.78 CA9 (0.40) CA9CA2CA12MEN1KMT2A
SCHEMBL26048161 0.74 CA9 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL26048155 0.74 CA9 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL30480962 0.74 CA9 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL23518159 0.74 CA9 (0.41) CA9CA2CA12MEN1KMT2A
SCHEMBL24132855 0.74 CA9 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL12041250 0.74 CA9 (0.33) CA9CA2CA12MEN1KMT2A
SCHEMBL5034447 0.73 SLC6A2 (0.34) CA9CA2
SCHEMBL26225205 0.73 SLC6A2 (0.34) CA9CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077797-A1 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES EMORY UNIVERSITY 2019-03-14 US claimed
EP-1300395-B1 4-SUBSTITUTED PIPERIDINE COMPOUND EISAI R&D MAN CO LTD (JP) 2009-09-02 EP claimed
US-7378425-B2 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-05-27 US claimed
EP-1491531-B1 (1-INDANONE)-(1,2,3,6-TETRAHYDROPYRIDINE) DERIVATIVE EISAI R&D MAN CO LTD (JP) 2007-12-26 EP claimed
US-6906083-B2 4-substituted piperidine compound EISAI CO., LTD. (JP) 2005-06-14 US claimed
US-20050124642-A1 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds EISAI CO., LTD. (JP) 2005-06-09 US claimed
CN-1184203-C 1-benzyl-4- [ (5, 6-dimethoxy-2-fluoro-1-indanone) -2-yl ] methylpiperidine EISAI CO LTD (JP) 2005-01-12 CN claimed
CN-1454209-A 1-benzyl-4- [ (5, 6-dimethoxy-2-fluoro-1-indanone) -2-yl ] methylpiperidine EISAI CO LTD (JP) 2003-11-05 CN claimed
US-20030166925-A1 4-Substituted piperidine compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2003-09-04 US claimed
EP-1316549-A1 1-BENZYL-4- (5,6-DIMETHOXY-2-FLUORO-1-INDANON)-2-YL] METHYLPIPERIDINE Eisai Co., Ltd. (JP) 2003-06-04 EP claimed
EP-1300395-A1 4-SUBSTITUTED PIPERIDINE COMPOUND Eisai Co., Ltd. (JP) 2003-04-09 EP claimed
EP-0885867-B1 Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds BASF AG (DE) 2001-10-24 EP claimed
US-6277866-B1 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine EISAI CO., LTD. (JP) 2001-08-21 US claimed
US-5973190-A Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds AMERICAN CYANAMID COMPANY (US) 1999-10-26 US claimed
EP-0885867-A1 Process and intermediate compounds for the preparation of pesticidal fluoroolefin compounds American Cyanamid Company (US) 1998-12-23 EP claimed
EP-4735445-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
US-12552754-B1 Leflutrozole compositions of matter and processes for preparation ReproNovo SA (CH) 2026-02-17 US disclosed
US-5246952-A Antitumor agents CIBA-GEIGY CORPORATION (US) 1993-09-21 US disclosed
US-5227393-A estrogen-dependent diseases, anticancer CIBA-GEIGY CORPORATION (US) 1993-07-13 US disclosed
US-5153358-A Process for the preparation of alpha-alkylated alpha-amino acids and alpha-halogenated alpha-amino acids ABBOTT LABORATORIES (US) 1992-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077797-A1 PROCESSES FOR PREPARING 2-DIHALO RIBOLACTONES DERA, DPYD, DUS2 CA9 2497/4885CA2 3122/4885CA12 3581/4885
US-12552754-B1 Leflutrozole compositions of matter and processes for preparation CYP19A1, CYP17A1, SHBG CA9 872/4885CA2 2489/4885CA12 1626/4885
US-20030166925-A1 4-Substituted piperidine compound ACHE, CHRM4, CHRM1 CA9 895/4885CA2 178/4885CA12 2066/4885
US-20050124642-A1 (1-Indanone)-(1,2,3,6-tetrahydropyridine) compounds SIGMAR1, CHRM1, ACHE CA9 4076/4885CA2 1340/4885CA12 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.